London, 19 March 2014. Rosetta Capital V L.P., an affiliate of Rosetta Capital
Ltd (“Rosetta”), a leading international life sciences secondary direct investor,
today announced that, with the backing of Lexington Partners, it has acquired the
equity interests in twenty companies from the corporate venture group of a major
pharmaceutical company.
“We are delighted to have completed this transaction with one of the world’s
leading pharmaceutical venture groups, and backed by the world’s largest
independent manager of secondary private equity and co-investment funds. It has
been a collaborative process in which we have worked closely with the corporate
venture team and Lexington Partners. This deal highlights Rosetta’s ability to
offer liquidity solutions to investors in the life science sector.” said Dr Jonathan
Hepple, a Partner in Rosetta.
This transaction is Rosetta’s fifth since its first secondary direct in 2006. Rosetta
invests in portfolios of shareholdings to provide liquidity to other investors or
corporations that, for strategic reasons, wish to divest some or all of their assets
or to access additional capital and resource to optimise investment outcomes.
Rosetta offers flexibility in transaction and management structures to achieve
such liquidity solutions.
Rosetta was advised by Kirkland & Ellis and Bluetower Associates, and Lexington
by Macfarlanes.
About Lexington Partners
Lexington Partners is a leading global alternative investment manager primarily
involved in providing liquidity to owners of private equity and other alternative
investments and in making co-investments alongside leading private equity
sponsors. Lexington Partners is the largest independent manager of secondary
acquisition and co-investment funds with more than $25 billion in committed
capital. Since 1990, Lexington has acquired over 2,200 secondary and coinvestment
interests through 475 transactions with a total value in excess of $30
billion, including $10 billion of syndications. Lexington also invests in private
investment funds during their initial formation and has committed to more than
200 new funds in the U.S., Europe, and the Asia-Pacific region. Lexington
currently employs more than 80 people and has offices strategically located in the
major centers for private equity investing – New York, Boston, Menlo Park,
London, and Hong Kong. Lexington also has senior advisors located in Asia,
Australia, and Latin America.
Additional information may be found at www.lexingtonpartners.com.
About Rosetta Capital Ltd
Rosetta is a UK-based firm that invests in portfolios of direct venture capital
investments in the life science sector. Rosetta’s funds encompass life science
companies across North America, Europe and Asia.
For more information, contact Jonathan Hepple: +44 7775 654140
jph@rosettacapital.com